Bellvitge Institute for Biomedical Research, Duran I Reynals Hospital
Holger Heyn obtained his PhD in 2009 at the Hannover Medical School (Hanover, Germany). In the Institute for Cellular and Molecular Pathology led by Prof. Dr. Brigitte Schlegelberger, he studied alterations of microRNA expression in cancer and in particular their function as regulatory factors controlling the expression of BRCA1. After joining the Cancer Epigenetic and Biology Program (Barcelona, Spain) directed by Dr. Manel Esteller he focused on the importance of epigenomic changes and especially DNA methylation alterations in disease and aging.
Analyzing data obtained from whole-genome shotgun bisulfite sequencing or high-resolution DNA methylation microarrays he is joining computational, statistical and biological knowledge in order to determine functional and clinical relevant epitype-phenotype associations. Using integrative prediction models, he is aiming to transfer epigenetic biomarkers and epigenomic signatures into clinical valuable tools. His main motivation and the major driving force of his work is the long-standing promise of a personalized patient therapy.